Fore Capital LLC acquired a new position in shares of Shire PLC (NASDAQ:SHPG) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,400 shares of the biopharmaceutical company’s stock, valued at approximately $527,000.
Other large investors have also recently made changes to their positions in the company. Morningstar Investment Services LLC raised its holdings in Shire by 53.0% during the third quarter. Morningstar Investment Services LLC now owns 25,882 shares of the biopharmaceutical company’s stock valued at $3,964,000 after buying an additional 8,969 shares in the last quarter. Boothbay Fund Management LLC bought a new position in Shire during the third quarter valued at about $4,338,000. Telemus Capital LLC bought a new position in Shire during the fourth quarter valued at about $350,000. FNY Partners Fund LP raised its holdings in Shire by 346.6% during the fourth quarter. FNY Partners Fund LP now owns 474,460 shares of the biopharmaceutical company’s stock valued at $73,598,000 after buying an additional 368,214 shares in the last quarter. Finally, Boston Partners raised its holdings in Shire by 60.9% during the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after buying an additional 886,572 shares in the last quarter. Institutional investors and hedge funds own 19.59% of the company’s stock.
Several equities analysts have weighed in on the company. Cowen set a $225.00 target price on Shire and gave the company a “buy” rating in a report on Friday, January 5th. Royal Bank of Canada set a $192.00 target price on Shire and gave the company a “buy” rating in a report on Monday, February 5th. BidaskClub lowered Shire from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Piper Jaffray Companies restated a “hold” rating on shares of Shire in a report on Wednesday, January 3rd. Finally, B. Riley cut their target price on Shire from $201.00 to $181.00 and set a “buy” rating on the stock in a report on Friday, February 16th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $204.00.
Shares of SHPG stock opened at $129.22 on Wednesday. The stock has a market capitalization of $40,482.99, a PE ratio of 9.20, a PEG ratio of 0.77 and a beta of 1.44. Shire PLC has a 1 year low of $123.73 and a 1 year high of $192.15. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.97 and a quick ratio of 0.55.
Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.86 by $0.12. The company had revenue of $4.14 billion for the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.37 earnings per share. sell-side analysts predict that Shire PLC will post 15.23 EPS for the current year.
The company also recently announced a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be given a dividend of $0.8937 per share. The ex-dividend date of this dividend is Thursday, March 8th. This is an increase from Shire’s previous semiannual dividend of $0.15. This represents a yield of 1.33%. Shire’s dividend payout ratio (DPR) is 7.47%.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.